# Orasure Technologies Inc: overview

OSUR · Nasdaq · CIK 1116463 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/osur.md) · [Financials](/companies/osur/financials.md) · [Filings](/companies/osur/filings.md) · [Insiders](/companies/osur/insiders.md)

Latest reported revenue: [$30.6m](/filings/0001116463-26-000052.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001116463-26-000052).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [39.9](/filings/0001116463-25-000054.md) | [37.4 d](/filings/0001116463-26-000016.md) | [29.9](/filings/0001116463-26-000041.md) | [31.2](/filings/0001116463-26-000052.md) | [27.1](/filings/0001116463-25-000054.md) | [26.8 d](/filings/0001116463-26-000016.md) | [27.9](/filings/0001116463-26-000041.md) | [30.6](/filings/0001116463-26-000052.md) |
| Gross margin | % | [42.8%](/filings/0001116463-25-000054.md) | [36.2% d](/filings/0001116463-26-000016.md) | [41.1%](/filings/0001116463-26-000041.md) | [42.1%](/filings/0001116463-26-000052.md) | [43.5%](/filings/0001116463-25-000054.md) | [41.0% d](/filings/0001116463-26-000016.md) | [42.3%](/filings/0001116463-26-000041.md) | [43.5%](/filings/0001116463-26-000052.md) |
| Operating margin | % | [(15.0%)](/filings/0001116463-25-000054.md) | [(33.2%) d](/filings/0001116463-26-000016.md) | [(59.3%)](/filings/0001116463-26-000041.md) | [(57.7%)](/filings/0001116463-26-000052.md) | [(59.4%)](/filings/0001116463-25-000054.md) | [(75.1%) d](/filings/0001116463-26-000016.md) | [(83.3%)](/filings/0001116463-26-000041.md) | [17.8%](/filings/0001116463-26-000052.md) |
| Net margin | % | [(11.3%)](/filings/0001116463-25-000054.md) | [(28.8%) d](/filings/0001116463-26-000016.md) | [(53.6%)](/filings/0001116463-26-000052.md) | [(63.0%)](/filings/0001116463-26-000052.md) | [(50.6%)](/filings/0001116463-25-000054.md) | [(72.1%) d](/filings/0001116463-26-000016.md) | [(80.1%)](/filings/0001116463-26-000052.md) | [20.4%](/filings/0001116463-26-000052.md) |
| Diluted EPS | $ per share | [(0.06)](/filings/0001116463-25-000054.md) | not reported | [(0.21)](/filings/0001116463-26-000041.md) | [(0.26)](/filings/0001116463-26-000052.md) | [(0.19)](/filings/0001116463-25-000054.md) | not reported | [(0.32)](/filings/0001116463-26-000041.md) | [0.09](/filings/0001116463-26-000052.md) |
| Free cash flow | $m | [12.5 d](/filings/0001116463-25-000054.md) | [(0.3) d](/filings/0001116463-26-000016.md) | [(20.2)](/filings/0001116463-26-000041.md) | [(12.2) d](/filings/0001116463-26-000052.md) | [(11.0) d](/filings/0001116463-25-000054.md) | [(9.9) d](/filings/0001116463-26-000016.md) | [(14.8)](/filings/0001116463-26-000041.md) | [(12.3) d](/filings/0001116463-26-000052.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [234](/filings/0001116463-24-000012.md) | [387](/filings/0001116463-25-000010.md) | [405](/filings/0001116463-26-000016.md) | [186](/filings/0001116463-26-000016.md) | [115](/filings/0001116463-26-000016.md) |
| Gross margin | % | [50.3%](/filings/0001116463-24-000012.md) | [38.3%](/filings/0001116463-25-000010.md) | [42.3%](/filings/0001116463-26-000016.md) | [42.7%](/filings/0001116463-26-000016.md) | [41.9%](/filings/0001116463-26-000016.md) |
| Operating margin | % | [(4.3%)](/filings/0001116463-24-000012.md) | [(5.7%)](/filings/0001116463-25-000010.md) | [8.1%](/filings/0001116463-26-000016.md) | [(15.2%)](/filings/0001116463-26-000016.md) | [(62.6%)](/filings/0001116463-26-000016.md) |
| Net margin | % | [(9.8%)](/filings/0001116463-24-000012.md) | [(4.4%)](/filings/0001116463-25-000010.md) | [13.2%](/filings/0001116463-26-000016.md) | [(10.5%)](/filings/0001116463-26-000016.md) | [(59.8%)](/filings/0001116463-26-000016.md) |
| Diluted EPS | $ per share | [(0.32)](/filings/0001116463-24-000012.md) | [(0.24)](/filings/0001116463-25-000010.md) | [0.72](/filings/0001116463-26-000016.md) | [(0.26)](/filings/0001116463-26-000016.md) | [(0.94)](/filings/0001116463-26-000016.md) |
| Free cash flow | $m | [(57.3)](/filings/0001116463-24-000012.md) | [(54.0)](/filings/0001116463-25-000010.md) | [136](/filings/0001116463-26-000016.md) | [23.6](/filings/0001116463-26-000016.md) | [(53.2)](/filings/0001116463-26-000016.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/osur/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $27.9m | 6,256,762 |  | Reduced −259,454 |
| [NEUBERGER BERMAN GROUP LLC](/funds/1465109.md) | 2026-06-30 | $20.9m | 4,685,432 |  | Added +323,531 |
| [PRIVATE MANAGEMENT GROUP INC](/funds/1142031.md) | 2026-06-30 | $16.9m | 3,797,682 |  | Reduced −1,624,447 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $13.5m | 3,018,907 |  | Reduced −11,981 |
| [SYSTEMATIC FINANCIAL MANAGEMENT LP](/funds/1085936.md) | 2026-06-30 | $12.7m | 2,857,974 |  | Added +377,491 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $10.4m | 2,340,901 |  | Reduced −479,929 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $9.0m | 2,014,903 |  | Reduced −68,400 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $8.1m | 1,807,889 |  | Reduced −12,130 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $7.5m | 1,686,609 |  | Reduced −18,171 |
| [GAGNON SECURITIES LLC](/funds/1125725.md) | 2026-06-30 | $7.1m | 1,592,147 |  | Reduced −122,244 |

## Recent filings

[All 1,075 filings](/companies/osur/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-17 | 20:08 ET | [SCHEDULE 13D](/filings/0000945621-26-001163.md) | Ownership report, active investor | 0000945621-26-001163 |
| 2026-08-07 | 16:04 ET | [10-Q](/filings/0001116463-26-000052.md) | Quarterly report, period 2026-06-30 | 0001116463-26-000052 |
| 2026-08-05 | 16:07 ET | [8-K](/filings/0001116463-26-000048.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001116463-26-000048 |
| 2026-06-11 | 09:02 ET | [8-K](/filings/0001116463-26-000046.md) | 8.01 Other events | 0001116463-26-000046 |
| 2026-06-03 | 16:32 ET | [8-K](/filings/0001116463-26-000043.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001116463-26-000043 |
| 2026-05-08 | 16:09 ET | [10-Q](/filings/0001116463-26-000041.md) | Quarterly report, period 2026-03-31 | 0001116463-26-000041 |
| 2026-05-06 | 16:09 ET | [8-K](/filings/0001116463-26-000037.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001116463-26-000037 |
| 2026-04-30 | 16:27 ET | [DEF 14A](/filings/0001116463-26-000032.md) | Proxy statement, period 2025-12-31 | 0001116463-26-000032 |
| 2026-04-20 | 08:02 ET | [SCHEDULE 13D/A](/filings/0000902664-26-002063.md) | Ownership report, active investor, amended | 0000902664-26-002063 |
| 2026-04-17 | 07:48 ET | [8-K](/filings/0001193125-26-160336.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-160336 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001116463-26-000016.md), filed Mar 9, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/aef395df-6f3b-4ad7-94ab-167724a9e1bc)

## About the filer

- CIK: 1116463
- Tickers: OSUR
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:39 ET. No prices; not investment advice.